Converting to a Generic Formulation of Mycophenolate Mofetil in Stable Kidney Transplant Recipients: 1 Year of Drug Surveillance and Outcome

Transplantation Proceedings

Volumn 39, Issue 3, 2007, Pages 602-605

  Videla, C ^a   Godoy, C ^a  

^a Medicine Faculty School of Medicine   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; KETOCONAZOLE; LINFONEX; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

AREA UNDER CURVE; AZATHIOPRINE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PREDNISONE; TREATMENT OUTCOME;

EID: 34147142273     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.12.034     Document Type: Article

References (12)

1. Danovitch G.M. Mycophenolate mofetil. A decade of clinical significance. Transplantation 80 (2005) 272
2. Denton M.D., Magee C.M., and Sayegh M.H. Immunosuppressive strategies in transplantation. Lancet 353 (1999) 1083
3. David-Neto E., Pereira L.M., Kakehashi E., et al. The need of mycophenolic acid monitoring in long-term renal transplants. Clin Transplant 19 (2005) 19
4. Cattaneo D., Gaspari F., Ferrari S., et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 15 (2001) 402
5. Foradori A., Mezzano S., Videla C., et al. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazole in stable adult kidney transplants. Transplant Proc 30 (1998) 1685
6. Srinivas T.R., Meier-Kriesche H., and Kaplan B. Pharmacokinetics principles of immunosuppressive drugs. Am J Transplant 5 (2005) 207
7. Shaw L.M., Korecka M., Venkataramanan R., et al. Mycophenolic acid pharmacodinamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 3 (2003) 534
8. Hesselink D.A., Van Hest R.M., Mathot R.A., et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5 (2005) 987
9. Videla C., Vega J., and Borja H. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adult renal recipients receiving ketoconazole. Transplant Proc 37 (2005) 1574
10. Van Hest R.M., Mathot R.A., Pescovitz M.D., et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mophetil dosing a population pharmacokinetic meto-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 17 (2006) 871
11. Mourad M., Malaise J., Chaib Eddour D., et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 47 (2001) 88
12. Engelbertink R., Gregoor P.S., Hesse J., et al. High mycophenolic acid area under-the-curve values in renal transplant recipients on long-term mycophenolate mofetil treatment. Transplant Proc 34 (2002) 2983